Region: Latin America & Caribbean

The biggest biopharma patent stories of the year

From President Biden’s backing for a covid IP waiver through a new linkage system in China to big changes in Brazil, it was an action-packed 2021 for the life sciences industries

21 December 2021

Phase II of Brazilian PPH hits its limit

Brazil has enjoyed consistent success with PPH programmes, as evidenced by Phase II of the programme starting and finishing considerably earlier than anticipated.

24 November 2021

The global patent landscape in nine charts

The top takeaways from WIPO’s latest World Intellectual Property Indicators report

19 November 2021

INPI decision clarifies when a preferential right to registration can be claimed

There has been confusion with regard to when an applicant can claim the preferential right to registration of a trademark. However, a fresh case provides some much-needed clarity.

17 November 2021

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine

02 November 2021

National IP Strategy aims to make Brazil a world-class hub for innovation

Brazil is seeking to improve its IP system by creating a National IP Strategy designed to stimulate innovation. This strategy aims to position Brazil among the 10 countries with the highest number of IP protection requests within the next decade.

27 October 2021

Position trademarks are now available for registration in Brazil

The Brazil National Institute for Industrial Property is now processing position marks. While some of the details still need to be ironed out, permitting such marks for registration signals a great step forward for brand protection in the country.

06 October 2021

INPI introduces new proceedings now that ANVISA´s prior approval for pharma patents is over

Brazil’s recent overhaul of its procedures for handling patents is well underway. So far it is yielding positive results, especially with regard to pharmaceutical and biotechnology patents.

22 September 2021

IAM Patent 1000 insights

Featured in Special Report 2021 Q3: IP leadership - what it is and why it matters

09 September 2021

Pharmaceutical patent applications are no longer subject to ANVISA’s prior approval

As the Brazilian Ministry of Economy looks to boost the country’s market by introducing new legal measures, pharmaceutical patent holders and future applicants will no longer be required to go through two regulatory bodies. This should make obtaining patent approval in Brazil a much smoother process.

08 September 2021